Compare Revvity Inc (RVTY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Growth Index Fund ETF — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while Vanguard Growth Index Fund ETF trades at $86.05. The key difference: Revvity Inc pays a 0.26% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| RVTY | VUG | |
|---|---|---|
Market Cap | $11.87B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $117.75 | $90.29 |
52-Week Low | $82.26 | $70.00 |
Enterprise Value | $14.36B | — |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
VUG trades at $85.32, up 0.06% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The ETF's growth-focused strategy, concentrated in large-cap U.S. companies, benefits from a low expense ratio of 0.03% and a decade-long track record of strong returns, though key financial ratios are not disclosed in the provided data. Recent news highlights its appeal for long-term investors seeking exposure to growth stocks.
The outlook for VUG is mixed, with technical weakness offset by positive sentiment for long-term growth potential. Risks include high tech concentration and market volatility, but analyst coverage emphasizes its cost efficiency and diversification benefits for buy-and-hold strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
